LEXINGTON, Mass.--(BUSINESS WIRE)--Synageva BioPharma Corp. (“Synageva”) (NASDAQ:GEVA), a clinical stage biopharmaceutical company developing therapeutic products for rare disorders, today announced the pricing of its previously announced underwritten public offering of common stock consisting of 2,150,000 shares at $47.53 per share. In connection with this offering, Synageva granted to the underwriters a 30-day option to purchase 322,500 additional shares of common stock. Morgan Stanley and J.P. Morgan are acting as joint book-running managers in the offering, and Cowen and Company, Canaccord Genuity Inc., and Leerink Swann LLC are acting as co-managers in the offering.
